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Abstract
Background: RRM1 and ERCC1 overexpression has been extensively investigated as potential predictive markers of
tumor sensitivity to conventional chemotherapy agents, most thoroughly in lung cancer. However, data in
pancreatic cancer are scarce.
Methods: We investigated the mRNA and protein expression of ERCC1 and RRM1 by RT-PCR and
immunohistochemistry (IHC) in formalin-fixed, paraffin-embedded pancreatic ductal carcinoma (PDA) tissues. The
primary outcome investigated was the association between RRM1 and ERCC1 expression and overall survival (OS)
or disease-free survival (DFS).
Results: A total of 94 patients with resected PDA were included in this study. Most of them (87%) received
gemcitabine based chemotherapy. Data for OS analysis was available in all cases but only 68% had enough
information to estimate DFS. IHC analysis revealed information for 99% (93/94) and 100% of the cases for RRM1
and ERCC1 expression respectively. However, PCR data interpretation was possible in only 49 (52%) and 79 (84%)
cases respectively. There was no significant association between high or low expression of either RRM1 or ERCC1,
detected by IHC and OS (14.4 vs. 19.9 months; P = 0.5 and 17.1 vs. 19.9; P = 0.83 respectively) or PCR and OS (48.0
vs. 24.1 months; P = 0.21 and 22.0 vs. 16.0 months; P = 0.39 respectively). Similar results were obtained for DFS.
Conclusions: RRM1 and ERCC1 expression does not seem to have a clear predictive or prognostic value in
pancreatic cancer. Our data raise some questions regarding the real clinical and practical significance of analyzing
these molecules as predictors of outcomes.
Background
Pancreatic ductal adenocarcinoma (PDA) is recognized as
the fourth leading cause of cancer-related mortality,
being responsible for almost 40,000 deaths per year in
the US [1]. Only 20% of the patients undergo surgical
resection and, with the exception of extremely rare cir-
cumstances, almost all patients receive some sort of che-
motherapy either as neoadjuvant, adjuvant or systemic
treatment of metastatic disease. For years, the traditional
approach included the use gemcitabine [2] or gemcita-
bine based combinations [3,4] as the standard of care.
This paradigm was recently challenged by the confirma-
tion that another regimen, which includes a combination
of 5-FU, leucovorin, oxaliplatin and irinotecan (FOLFIRI-
NOX) was superior to single agent gemcitabine in the
metastatic setting [5]. However this benefit was also
accompanied by a significant increase in grade 3-4 toxi-
city. This generates a practical clinical dilemma, espe-
cially in those patients who have poor performance status
and may not be able to tolerate this regimen. In that
sense, information regarding the tumor sensitivity to
gemcitabine - and to oxaliplatin - may have useful clini-
cally practical implications [6]. The ribonucleotide reduc-
tase subunit M1 (RRM1) and the excision repair cross
complementary 1 (ERCC1) enzymes are two of the many
proteins that physiologically participate in the synthesis
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and damage repair of human DNA. Both molecules have
been extensively investigated as potential predictive mar-
kers of tumor sensitivity to conventional chemotherapy
agents. RRM1 is directly affected by gemcitabine, consti-
tuting one of its molecular targets [7]. RRM1 inhibition
translates into reduced activity of the ribonucleotide
reductase complex resulting in decreased production of
deoxyribonucleotides needed for the DNA synthesis [8].
It is consequently easy to understand that over-expres-
sion of RRM1 can result in gemcitabine resistance [9].
ERCC1, on the other hand, seems to play a more relevant
role in the repair of DNA damage resulting from intra
and interstrand cross links [10]. Platinum analogues, as a
group, exert much of their therapeutic effects through
the induction of DNA adducts and cross-links [11]. Con-
sequently, over-expression of ERCC1 and other enzymes
able to remove those DNA adducts can translate into
tumoral resistance to platinum analogues [12,13]. These
two phenomenon have been consistently found to be
true especially in non-small cell lung cancer (NSCLC)
[14-19]; however it is unclear whether the same concept
can be applied to other cancer types, such as PDA. More-
over, it is also uncertain whether high levels of expression
of RRM1 and ERCC1 carry any prognostic significance
independently of the type of chemotherapy used. At least
one previous study showed a better overall survival asso-
ciated with high levels of RRM1 and ERCC1 in resected
PDA [20]. However, this work was never validated in an
independent cohort and the sample size was small.
We designed the present clinical study with the objec-
tive to determine whether quantification of RRM1 and
ERCC1 by immunohistochemical (IHC) and quantita-
tive-PCR analysis has any prognostic or predictive signif-
icance in PDA.
Methods
Patient selection and data collection
We studied 94 patients with confirmed PDA who under-
went surgical resection at The Thomas Jefferson Univer-
sity Hospital between 2002 and 2010, and for whom
sufficient material was available for immunohistochemical
(IHC) and polymerase chain reaction (PCR) analysis. All
had consented to analyses of their tumors via a protocol
approved by the Thomas Jefferson University Institutional
Review Board. We reviewed the medical charts and con-
tacted primary oncologists to obtain relevant clinical infor-
mation. Vital status was obtained from medical records
and verified by querying the Social Security death index.
The following variables were obtained for analysis: age,
gender, tumor size and grade, number of lymph nodes
resected, number of lymph nodes metastases, resection
margin involvement by tumoral cells, type of treatment
received (type of surgery, radiation therapy and che-
motherapy), time and site of first recurrence and death.
Figure 1 Staining for RRM1 and ERCC1 proteins. (A) ERCC1-positive sample. Note the intense nuclear staining. (B) ERCC1-negative sample. (C)
RRM1-positive sample. Note the intense cytoplasmic staining. (D) RRM1-negative sample.
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To ensure accuracy, dual data extraction was conducted.
Data were subsequently verified between the reviewers
and discrepancies resolved through consensus discussion.
To minimize subjective judgment and selection bias,
reviewers were blinded to clinical outcomes.
Immunohistochemical and PCR analysis
We investigated the mRNA and protein expression of
ERCC1 and RRM1 by RT-qPCR and immunohistochem-
istry (IHC) in formalin-fixed, paraffin- embedded PDA
tissues. Samples were sent by the investigators to
Response Genetics (Los Angeles, CA). Relative gene
expression quantification was calculated according to the
comparative cycle threshold (Ct) method using ß-actin as
an endogenous control and commercial RNA controls
(Stratagene, La Jolla, CA) as calibrators. Samples were
classified as “Low” or “High” expression according to cut
off values pre-established by Response Genetics (Los
Angeles, CA) [21]. The pancreatic cancer cases originally
tested by Response Genetic to establish those cuts off
values were not included in the study.
IHC was performed using purified RRM1 antibody
(1:150 dilution; Abcam, Cambridge, MA) and ERCC1
antibody (1:50 dilution; Abcam, Cambridge, MA). RRM1
and ERCC1 immunoreactivity was evaluated semi-quan-
titatively based on staining intensity and proportion of
staining in five representative fields at 400 × magnifica-
tion. ERCC1 was evaluated based on nuclear staining and
RRM1 based on cytoplasmic staining (Figure 1). The
stained tumor tissues were scored blindly with respect to
clinical patient data. For RRM1, the proportion of stain-
ing was scored on a scale from 0 to 3 as follows: > = 50%
positive (score 3); 10-49% positive (score 2); 1-9% positive
(score 1); negative (score 0). The intensity of staining was
scored from 0 to 3 as follows: 0 (absent), 1 (weak),
2 (moderate), 3 (intense). For ERCC1, the proportion of
staining was scored on a scale from 0 to 4 as follows:
> 50% positive (score 4); 25-50% positive (score 3);
10-24% positive (score 2); 1-9% positive (score 1); nega-
tive (score 0). The intensity of staining was scored from
0 to 3 as follows: 0 (absent), 1 (weak), 2 (moderate), 3
(intense) [12]. The immunoreactive score for each case
was determined by multiplying the proportion and inten-
sity scores. Criteria for positive staining were modeled
after previous work, requiring immunoreactive scores of
9 out of 9 and 6 out of 12 to be considered positive - or
high expression - for RRM1 and ERCC1, respectively
[22,23].
Outcomes and statistical analysis
The primary outcome was the association between RRM1
and ERCC1 expression - dichotomized as high or low -
and overall survival (OS) or disease-free survival (DFS).
OS was defined from the day of surgery to the day of
death or last follow-up. DFS was defined from the day of
surgery to the day of the first documented relapse or
death or last follow -up. Secondary outcomes include the
correlation between the IHC and PCR results found for
RRM1 and ERCC1 expression.
Patient characteristics were summarized using medians
and ranges for continuous variables and frequencies and
percentages for categorical variables. The distribution of
OS and DFS times was estimated using the Kaplan-Meier
method. The log-rank test was used to identify patient and
tumor characteristics significantly associated with OS and
DFS. Chi-square tests were used to identify covariates
associated with RRM1 and ERCC1 expression. Cox pro-
portional hazards regression was used to test for
Table 1 Clinico-pathologic characteristics of the 94
patients
Characteristics N° of Patients (%) Median (range)
Age (years) 94 66 (35-89)
Gender
Male 53 (56%)
Female 41 (44%)
Size, cm 3 (0-9.5)
Histological Grade
1 5 (5%)
2 69 (73%)
3 18 (19%)
4 1 (1%)
(Unknown)¥ 1 (1%)
Tumor Size (T)
1-2 15 (16%)
3-4 78 (83%)
(Unknown) ¥ 1 (1%)
Nodes (N)
Positive 65 (69%)
Negative 27 (29%)
(Unknown) ¥ 2 (2%)
TNM Stage
IA 2 (2%)
IB 3 (3%)
IIA 21 (22%)
IIB 63 (67%)
III 3 (3%)
IV 2(2%)
Resection Margins
R0 66 (70%)
R1 27 (29%)
(Unknown) ¥ 1 (1%)
Vital status
Alive 34 (36%)
Dead 60 (64%)
¥ This corresponds with patients with metastatic disease for whom this
variable could not be obtained
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association of RRM1 and ERCC1 expression with OS after
adjustment for potential confounders. Spearman rank cor-
relations were calculated to test for association among
RRM1 and ERCC1 gene expression levels and IHC scores.
Results
A total of 94 patients were included in this study, with a
median age of 65 years (range: 35-89 years). The median
follow up was 15 months. The baseline clinic-pathologic
characteristics of the patients are summarized in Table 1.
From the whole cohort, 87.2% (82 cases) received gemci-
tabine based chemotherapy and in 12 cases chemother-
apy was not administered. Data for OS analysis were
available in all cases but only 64 patients (68%) had
enough information to estimate DFS. IHC analysis
revealed information for 99% (93/94) and 100% of the
cases for RRM1 and ERCC1 expression, respectively.
However, PCR data interpretation was possible only in
49 (52%) and 79 (84%) cases respectively.
There was no significant difference between high or
low expression of either RRM1 or ERCC1, detected by
IHC or PCR, and any of the clinic-pathological variables
analyzed, which included age, race, gender, tumor size,
pathological depth (pT), histological grade and presence
of metastatic lymph nodes (Table 2).
The median survival of the entire cohort was 18
months (CI: 14-25). In the univariate analysis the vari-
ables associated with better OS were younger age (< 65.5
years; P = 0.087), histological grade 1 or 2 (P = 0.003),
absence of lymph node metastases (P = 0.009) and use of
chemotherapy (P < 0.001). However, there was no signifi-
cant association between high or low expression of either
RRM1 or ERCC1, detected by IHC and OS (14.4 vs. 19.9
months; P = 0.5 and 17.1 vs. 19.9; P = 0.83 respectively)
or PCR and OS (48.0 vs. 24.1 months; P = 0.21 and 22.0
vs. 16.0 months; P = 0.39 respectively) (Figures 2 and 3).
Similar results were obtained with DFS where only histo-
logical grade 1 or 2 (P = 0.031), absence of lymph node
metastases (P = 0.08) and use of chemotherapy (P =
0.013) showed significant longer DFS. The same as in
OS, the expression levels of RRM1 or ERCC1 detected by
IHC or by PCR did not showed any statistically signifi-
cant result (Table 3). Using Cox regression multivariate
analysis the expression levels of RRM1 and ERCC1 were
not significant associated with any change in the OS or
the DFS using IHC (Table 4). RRM1 was associated with
OS using PCR after adjustment for other predictors of sur-
vival. The exclusion of the 12 patients who did not receive
a full course of chemotherapy did not make any significant
change in the estimates (Table 5).
Table 2 Covariates and RRM1 or ERCC1 (Patient N, row%)
RRM1 Expression ERCC1 Expression
RRM1 mRNA
expression (PCR)
RRM1 protein
expression (IHC)
ERCC1 mRNA
expression (PCR)
ERCC1 protein
expression (IHC)
Covariate High Low N p High Low N p High Low N p High Low N p
Age (years)
Young (<65.5) 4 (21%) 15 (79%) 49 1.0 14 (30%) 32 (70%) 93 0.51 19 (48%) 21 (53%) 79 0.36 29 (62%) 18 (38%) 94 0.41
Old (> 65.5) 6 (20%) 24 (80%) 18 (38%) 29 (62%) 14 (36%) 25 (64%) 24 (51%) 23 (49%)
Size (cm)
Small (<2.0) 1 (9%) 10 (91%) 49 0.42 5 (26%) 14 (74%) 93 0.59 4 (31%) 9 (69%) 79 0.54 11 (55%) 9 (45%) 94 1.0
Large (> 2.0) 9 (24%) 29 (76%) 27 (36%) 47 (64%) 29 (44%) 37 (56%) 42 (57%) 32 (43%)
Gender
Female 6 (24%) 19 (76%) 49 0.73 14 (35%) 26 (65%) 93 1.0 13 (37%) 22 (63%) 79 0.50 25 (61%) 16 (39%) 94 0.53
Male 4 (17%) 20 (83%) 18 (34%) 35 (66%) 20 (45%) 24 (55%) 28 (53%) 25 (47%)
Race
White 4 (12%) 29 (88%) 48 0.11 23 (35%) 43 (65%) 92 1.0 22 (42%) 31 (58%) 78 1.0 36 (55%) 30 (45%) 93 0.82
Non-White 5 (33%) 10 (67%) 9 (35%) 17 (65%) 11 (44%) 14 (56%) 16 (59%) 11 (41%)
Histological Grade¥
1 or 2 7 (19%) 29 (81%) 48 1.0 22 (30%) 51 (70%) 92 0.10 27 (45%) 33 (55%) 78 0.43 42 (57%) 32 (43%) 93 0.80
3 or 4 2 (17%) 10 (83%) 10 (53%) 9 (47%) 6 (33%) 12 (67%) 10 (53%) 9 (47%)
Lymph Nodes¥
No LN positive 4 (31%) 9 (69%) 47 0.24 9 (35%) 17 (65%) 91 1.0 14 (64%) 8 (36%) 77 0.024 16 (59%) 11 (41%) 92 0.82
At least 1 LN positive 5 (15%) 29 (85%) 23 (35%) 42 (65%) 19 (35%) 36 (65%) 36 (55%) 29 (45%)
Depth of Tumor (pT) ¥
T1 and T2 2 (20%) 8 (80%) 48 1.0 4 (27%) 11 (73%) 92 0.56 4 (36%) 7 (64%) 78 0.75 5 (33%) 10 (67%) 93 0.087
T3 and T4 7 (18%) 31 (82%) 28 (36%) 49 (64%) 29 (43%) 38 (57%) 47 (60%) 31 (40%)
¥ The difference in values corresponds to the patients with metastatic disease only, for whom some variables were not able to be computed.
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In regards to the correlation between IHC and PCR
analysis, we found a borderline significant association
between RRM1 expression by IHC and PCR (r = 0.26;
P = 0.07) and the same result was applicable for ERCC1
expression (r = 0.21; P = 0.07). However there was a
strong positive correlation between the RRM1 and the
ERCC1 gene expression detection by PCR (r = 0.57; P <
0.0001) (Table 6).
Discussion
The results obtained in this study showed no significant
correlation between the protein or mRNA expression
levels of RRM1 and ERCC1 - detected by IHC or PCR -
and OS or DFS in patients with resected PDA. Our data
raise some questions regarding the real clinical and practi-
cal significance of analyzing these molecules as predictors
of outcomes. Low levels of RRM1 did not predict better
outcomes which, since the majority of our patients
received gemcitabine based chemotherapy regimens,
would have indirectly represented more tumor sensitivity
to this agent.
The role of ERCC1 in PDA is less clear and since practi-
cally no patient received platinum analogue agents in this
cohort, we cannot deduce the importance of ERCC1 as a
predictor of oxaliplatin-based regimens as previously sug-
gested [24,25]. Yet it seems to be clear that ERCC1 expres-
sion levels do not have any prognostic value in this patient
cohort who did not receive platinum based chemotherapy.
Future investigations should explore the significance of
ERCC1 in patients receiving platinum based regimens.
Our results are discordant with what was previously
reported by Akita and colleagues who found borderline
better outcomes in patients with high expression levels of
RRM1 and ERCC1 [20]. Nonetheless, in that study only a
minority of patients received adjuvant chemotherapy (5/
68) and in total only 40% received gemcitabine during
the course of their treatment. Our population is unique
and quite different to this previous work since the major-
ity of our patients (87%) received gemcitabine in the
adjuvant setting. Our study is more in accordance and
relevant to current practices in the U.S. (i.e., standard of
care therapy); hence our conclusions are directly
Figure 2 Kaplan Meier curve for overall survival according
RRM1 expression by: A) - IHC (P = 0.5) and B) - PCR (P = 0.21).
Figure 3 Kaplan Meier curve for overall survival according
ERCC1 expression by: A) - IHC (P = 0.83) and B) - PCR (P =
0.39).
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applicable to the majority of patients who seek medical
attention after a resection of a PDA. However the median
OS in our cohort (18 months) was slightly inferior to that
previously reported in randomized clinical trials (i.e.: in
Conko-001, 22 months) [26]; this could be attributed to
the more heterogeneous population of our study in com-
parison to one that could be observed in prospective and
controlled clinical trials.
There are some studies that support the role of RRM1
over-expression as a source of resistance to gemcitabine in
PDA [27,28]. One study showed that in gemcitabine resis-
tant cell lines, sensitivity to this agent could be rescued by
silencing the RRM1 expression (> 90%) with iRNA [10]. A
similar correlation between RRM1 expression and gemci-
tabine efficacy was observed in the clinical setting but only
in NSCLC [16]. However, during the last couple of years
many other genes have been described as potential source
of gemcitabine resistance in pancreatic tumoral cells,
including human equilibrative nucleoside transporter-1
(hENT1) [29,30], deficiency in deoxycytidine kinase (dCK)
[31], over-expression of RRM2 [32] and HuR [6,33]. The
roles played by each particular gene in addition to the pos-
sible still undiscovered genes and pathways in the gemcita-
bine metabolism process, coupled with the complex in-
vivo environment, are still under investigation [34]. How-
ever, some studies have already shown that the combina-
tion of detecting the expression of a select set of genes
rather than the particular expression of one gene may play
a more relevant, realistic clinical role [35,36]. Moreover,
our own group has previously shown a notoriously more
predictive value of HuR for gemcitabine sensitivity, which
is most likely due to its ability to affect a myriad of down-
stream target genes [33]. Additionally, a recent report
found also no prognosis value of RRM1 in PDA [37]
Taking all this evidence together, in conjunction with
the results of the present study, we believe that the iso-
lated detection of RRM1 or ERCC1 expression in PDA
has little clinical relevance and deserves further
Table 3 Univariate Overall and Disease-Free Survival: Kaplan-Meier medians and log-rank test
Overall Survival Disease-Free Survival
Covariate Median [months] (95%
CI)
N Total
N
Log-rank p-
value
Median [months] (95%
CI)
N Total
N
Log-rank p-
value
Overall 18 (14, 25) 94 94 12 (8, 19) 64 64
Age (year) Young (≤
65.5)
20 (16, 47) 47 94 0.087 11 (8, 19) 38 64 0.71
Old (> 65.5) 15 (9, 24) 47 14 (7, 25) 26
Size (cm) Small (≤ 2.0) 25 (9, 47) 20 94 0.60 21 (8, ∞) 12 64 0.17
Large (> 2.0) 17 (13, 22) 74 11 (7, 17) 52
Gender Female 20 (12, 34) 41 94 0.89 10 (7, 17) 32 64 0.12
Male 18 (12, 25) 53 19 (9, 46) 32
Race White 17 (13, 26) 66 93 0.65 14 (8, 25) 43 64 0.59
NonWhite 22 (8, 26) 27 10 (6, 19) 21
Grade 1/2 20 (16, 26) 74 93 0.003 14 (10, 19) 52 64 0.031
3/4 7 (6, 14) 19 6 (2, 25) 12
Lymph
Nodes
0 26 (22, 48) 27 92 0.009 21 (14, ∞) 20 63 0.008
≥ 1 15 (12, 20) 65 9 (7, 12) 43
Tumor size
by
1/2 12 (6, 22) 15 93 0.45 19 (5, ∞) 9 64 0.31
TNM stage 3/4 18 (15, 26) 78 11 (8, 19) 55
Treatment Chemo 20 (15, 26) 82 94 <.001 14 (9, 19) 62 64 0.013
No chemo 6 (3, ∞) 12 5 2
RRM1 Low 20 (15, 25) 61 93 0.50 12 (8, 21) 40 63 0.76
IHC Interp. High 14 (8, 48) 32 17 (5, ∞) 23
RRM1 Low 24 (16, 26) 39 49 0.21 14 (8, 21) 28 34 0.48
PCR Interp. High 48 (3, 48) 10 17 (11, 17) 6
ERCC Low 20 (12, 25) 41 94 0.83 14 (8, 25) 26 64 0.39
IHC Interp. High 17 (12, 26) 53 12 (7, 19) 38
ERCC Low 16 (12, 25) 46 79 0.39 10 (7, 19) 29 56 0.74
PCR Interp. High 22 (9, 48) 33 14 (6, 21) 27
Abbreviations: ∞ = infinity; Interp. = Interpretation
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Table 4 Multivariate cox regression analysis for overall survival
A. Survival in Pancreatic CA: Relative Gene Expression (N = 42)
Multivariate
Variable (Comparison) Hazard Ratio
(95% CI)
p-value†
Year of Diagnosis one year increase 0.97 (0.69, 1.35) 0.836
Age ≥ 65.5 vs. < 65.5 1.53 (0.54, 4.33) 0.419
Positive Lymph Nodes Any vs. None 0.80 (0.29, 2.22) 0.672
Treatment received No Chemo vs. Chemo 13.09 (1.71,100.2) 0.013
ERCC1 Rel Gene Expression (PCR) Low vs. High 0.86 (0.26, 2.81) 0.797
RRM1 Rel Gene Expression (PCR) Low vs. High 17.58 (1.45,213.5) 0.024
B. Survival in Pancreatic CA: Protein Expression by IHC Score (N = 91)
Multivariate
Variable (Comparison) Hazard Ratio
(95% CI)
p-value†
Year of Diagnosis one year increase 0.86 (0.71, 1.02) 0.088
Age ≥ 65.5 vs. < 65.5 1.36 (0.74, 2.52) 0.320
Positive Lymph Nodes Any vs. None 2.34 (1.21, 4.52) 0.011
Treatment No Chemo vs. Chemo 3.04 (1.25, 7.41) 0.014
ERCC1 IHC Low vs. High 0.96 (0.53, 1.74) 0.888
RRM1 IHC Low vs. High 0.83 (0.42, 1.63) 0.583
Stratified by Grade
† Cox regression
Table 5 Overall and Disease-Free Survival using Kaplan-Meier and log-rank test but only in patients who received
complete chemotherapy regimen (all of whom received gemcitabine)
Overall Survival Disease-Free Survival
Covariate Median [months] (95% CI) N Total N Log-rank
p-value
Median [months] (95% CI) N Total N Log-rank
p-value
Overall 20.3 (15, 25.5) 82 82 13.5 (9.3, 19.4) 62 62
Age Young (≤ 65.5) 22 (15.6, 47.2) 44 82 0.18 10.5 (8, 19.3) 38 62 0.48
Old (> 65.5) 17 (9.6, 25.5) 38 14 (8, ∞) 24
Size Small (≤ 2.0) 25 (9.6, 47.2) 18 82 0.45 20.5 (8.3, ∞) 12 62 0.21
Large (> 2.0) 17.7 (14.8, 25.5) 64 12 (8, 17.3) 50
Gender Female 22 (14.8, 34.5) 36 82 0.85 10 (6.5, 17.3) 31 62 0.12
Male 20 (14.4, 25.5) 46 19.3 (9.4, 46) 31
Race White 20 (14.8, 26.5) 59 82 0.88 13.5 (8, 25.5) 42 62 0.65
Non-White 22 (9.2, 26.2) 23 10.3 (5.5, 592) 20
Grade 1/2 20.5 (16, 25.5) 67 82 0.028 14 (10.3, 20.5) 51 62 0.0503
3/4 14.5 (6.5, 26.5) 15 9.4 (2, 25.5) 11
Lymph Nodes 0 25.5 (15, 48.5) 26 81 0.038 20.5 (13.5, ∞) 20 61 0.012
≥ 1 16 (13, 20.3) 55 9.4 (6.5, 14) 41
Tumor 1/2 20 (6.5, 47) 13 82 0.59 19.5 (5.5, ∞) 8 62 0.21
(TNM) 3/4 20.5 (15, 26) 69 12 (8, 19.3) 54
RRM1 Low 20.3 (15, 25.5) 55 81 0.87 13.5 (8, 20.5) 39 61 0.84
IHC Interp High 47.8 (8.7, 48) 26 16.6 (5.5, ∞) 22
RRM1 Low 24 (17, 26) 37 44 0.070 14 (9.4, 25.5) 26 32 0.62
PCR Interp High 48 (*, *) 7 17.3 (10.5, 17.3) 6
ERCC Low 20.3 (14.8, 26.5) 35 82 0.88 14 (9.4, 31.5) 25 62 0.36
IHC Interp High 17 (13.3, 26) 47 12 (6.5, 20.5) 37
ERCC Low 17 (14.5, 24.7) 39 68 0.23 10 (7, 25.5) 28 54 0.74
PCR Interp High 24 (11, 63.7) 29 13.5 (8, 20.5) 26
* The 95% confidence interval could not be estimated since only one event (death) was recorded.
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investigation before formal recommendation regarding
its use in clinical practice can be made. In addition, our
study also serves as evidence that the information gath-
ered from other tumor types (i.e.: lung cancer) should
not always be directly applied to other cancers (especially
to PDA where the aggressive biology appears to be
unique) without the appropriate confirmation of these
assumptions. In the particular cases of NSCLC, this dis-
cordance could also be partially explained by the fact that
the overall response rate of gemcitabine in PDA is 5-7%
[4] in comparison to the 20% found in NSCLC [38],
meaning that lung cancer is intrinsically more sensitive
to gemcitabine and levels of RRM1 may play a more rele-
vant role.
Lastly, we should also take into consideration the fact
that our study has some limitations which are mainly
derived from its retrospective nature. We were not able
to obtain reliable information to calculate DFS in one
third of the cases since some patients were lost in follow
up or the information available was inaccurate. As
expected, this raises some concerns regarding selection
bias in our cohort and conclusions regarding this matter
should be analyzed cautiously and confirmed in future
studies. However, we were able to estimate OS in all
cases and, as mentioned before, given the very modest
effect of second and third line chemotherapy regimens in
PDA it is very unlikely that gross and undetected misba-
lance of these variables would have changed the results
considerably. Additionally, we cannot directly translate
our results to the metastatic setting since only 2 patients
debuted with a stage IV disease. Other sources of varia-
bility could be related to the cut off values used for PCR
detection or to the fact that only half of the patients stu-
died had reliable information in regards to the gene
expression, thus underscoring the difficulty of realistically
utilizing this assay for clinical purposes. Indeed, when
analyzing only those patients who received a complete
regimen of chemotherapy, high RRM1 gene expression
(PCR) showed a trend toward significance (P = 0.07) but
the number of patients investigated was too small (N =
7) and results could be due to random sampling variabil-
ity. We tried to correlate the gene and protein expression
levels and we found a borderline significant correlation,
but not a direct one. We cannot then discard the possibi-
lity that newer and more reliable techniques of gene
expression detection could produce different results.
Nonetheless, the current available evidence argues
against this possibility.
Conclusions
In conclusion, RRM1 and ERCC1 expression does not
seem to have a clear predictive or prognostic value in
resected PDA patients. Future studies will elucidate the
role of these biomarkers in other tumor types and in
PDA patients who present with metastatic disease.
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